Clinical Trials for Prostate Cancer

A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with previously treated, locally advanced/metastatic small cell lung cancer or other neuroendocrine tumors (e.g., LCNEC, NEPC, high‑grade GI‑NET, Merkel cell) receive BL‑M14D1, an investigational DLL3‑targeted antibody–drug conjugate with a topoisomerase I inhibitor payload, given IV every 21 days. Suitable for ECOG 0–1 patients post‑standard therapy (SCLC requires prior platinum); excludes prior topo‑I ADCs, significant cardiac/QTc issues, ILD/pneumonitis, active CNS disease, and uncontrolled infections.

ClinicalTrials.gov ID: NCT07080242

A Phase I/II Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6621, a T Cell-engaging Antibody That Targets STEAP2, CD3, and CD8 in Adult Participants With Metastatic Prostate Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with metastatic castration‑resistant prostate adenocarcinoma (ECOG 0–1) after progression on ADT receive AZD6621 monotherapy, a multispecific T‑cell–engaging antibody targeting STEAP2 on tumor cells and CD3/CD8 to preferentially activate CD8+ T cells; two administration routes are explored with dose escalation and expansion. Key exclusions include significant cardiac disease/QT prolongation, uncontrolled autoimmune disease, prior severe CRS/ICANS, active CNS disease, and recent cellular therapy.

ClinicalTrials.gov ID: NCT07192614

A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0516 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Metastatic Prostate Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with metastatic castration‑resistant prostate adenocarcinoma (ECOG 0–1) with documented progression and adequate organ function receive AZD0516, a STEAP2‑targeted antibody–drug conjugate delivering an exatecan topoisomerase I inhibitor, either as monotherapy or combined with AZD9574 (palacaparib), a selective PARP1 inhibitor. Requires available tumor tissue; excludes prior STEAP2‑targeted therapy and significant CNS, pulmonary, infectious, or cardiovascular comorbidities.

ClinicalTrials.gov ID: NCT07181161

Phase 1, Dose-Escalation Study of KTX2001 (an NSD2 Inhibitor) Alone and in Combination With Darolutamide for Metastatic Castration-Resistant Prostate Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adult men with metastatic castration-resistant prostate cancer after at least one AR pathway inhibitor, ECOG 0–1, receive oral KTX-2001 (first-in-class NSD2 histone methyltransferase inhibitor targeting H3K36me2) as monotherapy or combined with darolutamide 600 mg BID. Excludes unstable CNS disease and significant cardiac/infection risks; aims to establish safety, PK/PD, and preliminary activity to define MTD/RP2D.

ClinicalTrials.gov ID: NCT07103018

A Phase I, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with DLL3-expressing advanced solid tumors, including previously treated SCLC or LCNEC (dose escalation) and expansion cohorts of SCLC (≤2 prior lines), de novo or treatment-emergent NEPC, and GEP-NEC; some cohorts require demonstrable uptake on 111In-ETN029 SPECT. Single-arm therapy with 225Ac-ETN029, a DLL3-targeted alpha-emitting radiopharmaceutical delivering actinium-225 to tumor cells, with optional 111In-ETN029 imaging/dosimetry.

ClinicalTrials.gov ID: NCT07006727

An Open-Label, Phase 1/2 Study to Evaluate Safety, Efficacy, and Pharmacokinetics of EU101, an Agonistic Anti-CD137 (4-1BB) Monoclonal Antibody in Patients With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial is focused on patients with metastatic or locally advanced solid tumors, specifically colorectal cancer and non-small cell lung cancer, investigating the safety and efficacy of EU101, an agonistic monoclonal antibody targeting the 4-1BB receptor to enhance immune response.

ClinicalTrials.gov ID: NCT04903873

A Phase 1/2 Study of Oral MRT-2359 in Patients With MYC-Driven and Other Selected Solid Tumors Including Lung Cancer and Diffuse B-Cell Lymphoma

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls adults with previously treated advanced MYC-driven or selected solid tumors—including NSCLC, SCLC, high-grade neuroendocrine cancers, L- or N-MYC amplified solid tumors, or diffuse large B-cell lymphoma—testing oral MRT-2359, a GSPT1-targeting molecular glue degrader, as monotherapy or in combination with fulvestrant (HR+/HER2- breast cancer) or enzalutamide (prostate cancer).

ClinicalTrials.gov ID: NCT05546268

A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage Lymphoma Proto-oncogene (CBL-B) Inhibitor, in Adults With Advanced Malignancies, With Phase 1b Expansion in Select Tumor Types

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls adults with advanced or metastatic solid tumors or diffuse large B-cell lymphoma who have exhausted standard therapies, evaluating the investigational oral CBL-B inhibitor NX-1607 (which enhances antitumor immunity by blocking a negative regulator of immune cell activation) as monotherapy or in combination with paclitaxel. Eligible tumor types include ovarian, gastric, head and neck, melanoma, NSCLC, prostate, mesothelioma, triple-negative breast, urothelial, cervical, microsatellite-stable colorectal cancer, and DLBCL/Richter transformation.

ClinicalTrials.gov ID: NCT05107674

A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls adults with advanced, measurable solid tumors (including separate cohorts for breast, pancreatic, or gastric cancer) who have progressed after standard therapy, testing Minnelide—a prodrug of triptolide that inhibits HSP70 with downstream anti-oncogenic effects—given alone or in combination with protein-bound paclitaxel. Patients must have good performance status and adequate organ function.

ClinicalTrials.gov ID: NCT03129139

A Phase I/II, Open Label, Multi-center, Non-randomized Dose Escalation and Dose Expansion Study of AMXI-5001 in Patients With Advanced Malignancies

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with advanced or metastatic solid tumors that are refractory to, have progressed after, or are intolerant to standard therapies may receive oral AMXI-5001, a novel dual PARP1/2 and microtubule polymerization inhibitor, as monotherapy in this open-label study. Participants must have ECOG 0-1 and measurable or evaluable disease; no concurrent cancer therapy or strong CYP3A4 modulators are allowed.

ClinicalTrials.gov ID: NCT04503265